|

Fluzoparib Clinical Trials

11 actively recruiting trials

No change since May 2026

Also known as: SHR-3162, SHR3162

Pipeline

Phase 2: 9Phase 3: 2

Top Sponsors

  • Fudan University4
  • Qilu Hospital of Shandong University2
  • Ying Lin1
  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University1
  • Huazhong University of Science and Technology1

Indications

  • Cancer11
  • Breast Cancer6
  • Hormone Receptor Positive Tumor2
  • HER2-negative Breast Cancer2
  • Breast Neoplasm2

Other11 trials

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma
Phase 2
Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer
Phase 2
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Phase 3
Fluzoparib Neoadjuvant Therapy for Ovarian Cancer
Phase 2
Fluzoparib With or Without Bevacizumab for Neoadjuvant Therapy in Advanced Ovarian Cancer
Phase 2
Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
Phase 2
Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Phase 2
PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Phase 2
Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer
Phase 3
SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC
Phase 2
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.